A Novel <i>AKT1</i>, <i>ERBB2</i>, <i>ESR1</i>, <i>KRAS</i>, <i>PIK3CA</i>, and <i>TP53</i> NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors

<b>Background</b>: Patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (mBC) generally receive hormonal therapy (HT) combined with CDK4/6 inhibitors (CDK4/6i). Despite this treatment, resistance mechanisms to CDK4/6i emerge and the majority of these patients experience disea...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Alessandra Virga, Caterina Gianni, Michela Palleschi, Davide Angeli, Filippo Merloni, Roberta Maltoni, Paola Ulivi, Giovanni Martinelli, Ugo De Giorgi, Sara Bravaccini
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2024-09-01
Serier:	Biomedicines
Fag:	hormone receptor-positive metastatic breast cancer patients CDK4/6 inhibitors resistance novel multi-gene target panel NGS assay
Online adgang:	https://www.mdpi.com/2227-9059/12/10/2183
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!